CASE REPORT

IgG4 related pleural disease: Recurrent pleural effusion after COVID-19 vaccination

Saria Tasnim1 | Ola Al-Jobory1 | Ahmad Hallak2 | Taru Bharadwaj1 | Manish Patel1

1Department of Internal Medicine, Texas Tech University Health Sciences Center, Amarillo, Texas, USA
2Department of Vascular Medicine, Ochsner Medical Center, New Orleans, Louisiana, USA

Correspondence
Saria Tasnim, Texas Tech University Health Sciences Center, Internal Medicine, 1400 S Coulter Street, Amarillo, TX, USA, 79106.
Email: satasnim@ttuhsc.edu

Associate Editor: Coenraad F. Koegelenberg

Abstract
IgG-related disease is characterized by a systemic fibroinflammatory process associated with substantial infiltration by plasma cells with IgG4 in the organs. Our patient presented with pleural effusion, and was diagnosed with IgG4-related lung disease (IgG4-RLD) after he received two doses of the Pfizer COVID-19 vaccine. The patient developed dyspnea and hypoxia 2 weeks after receiving the second dose of the Pfizer COVID-19 vaccine. CT scan revealed left pleural effusion which was drained. However, the effusion recurred requiring thoracoscopic drainage, placement of an indwelling catheter, and decortication with biopsy. IgG4 serum level was 268 mg/dl and pathology revealed pleural fibrosis, lymphoplasmacytic infiltrates, and increased IgG4-positive plasma cells with no malignant cells leading to a diagnosis of IgG4-RLD. Although COVID vaccine-related IgG4-RLD is a novel finding, having a high degree of suspicion following vaccination is always important for early diagnosis and effective treatment.

KEYWORDS
COVID-19 vaccine, IgG4-related disease, IgG4-related lung disease, Pfizer vaccine, pleural effusion

INTRODUCTION

IgG4-related disease (IgG-RD) is a poorly understood inflammatory disease. It is a systemic fibroinflammatory process associated with substantial infiltration by plasma cell with IgG4. Since the COVID era, great effort went into finding a vaccine to decrease the impact of the virus, several companies achieved their goal by finding a vaccine, including the Pfizer vaccine which is a segment of mRNA of the virus wrapped with lipid nanoparticles to activate the immune system. Although, side effects related to the Pfizer vaccine are benign, very rarely, it can lead to IgG-RD.

CASE REPORT

Our patient is a 71-year-old male with hypertension, coronary artery disease, prostate cancer and chronic obstructive pulmonary disease with a 50-pack year smoking history. The patient started being followed in the pulmonology department after a screening chest CT revealed left hilar fullness and peri-fissural nodules, the largest of which measured 0.4 cm (Figure 1). Repeat CT 2 years later showed unchanged nodules, with two new nodules measuring 0.4 cm. At this point, he elected not to continue surveillance.

Two years later, he received a first dose of the Pfizer COVID-19 vaccine and visited urgent care after a week with wheezing and dyspnea which improved with albuterol. However, he returned to clinic with dyspnea 2 weeks after receiving the second dose of the vaccine. He underwent pulmonary function testing which revealed a mixed obstructive and restrictive pattern with reduced DLCO. Six-minute walk test revealed hypoxia requiring 3 L oxygen.

Chest CT revealed new left pleural effusion with atelectasis (Figure 2). 1.4 L straw-coloured exudative fluid was removed by thoracentesis which was negative for malignant cells. Summary of the laboratory, pulmonary function test and pleural fluid analysis of our case are shown in Table 1. His symptoms initially improved but worsened again. Repeat CT scan 10 days later revealed large left pleural effusion, which was drained. Pathology revealed pleural fibrosis, lymphoplasmacytic infiltrates, and increased IgG4-positive plasma cells with no malignant cells leading to a diagnosis of IgG4-RLD. Although COVID vaccine-related IgG4-RLD is a novel finding, having a high degree of suspicion following vaccination is always important for early diagnosis and effective treatment.
effusion. He was referred to thoracic surgery and underwent left thoracoscopy with drainage of 2.5 L of pleural fluid followed by pleural biopsy and chemical pleurodesis with insertion of an indwelling tunneled pleural catheter. Pleural biopsy revealed chronic organizing pleuritis with lymphoid hyperplasia and reactive mesothelial hyperplasia.

The pleural catheter continued to drain for 3 months. Eventually, it stopped draining but oxygen requirement increased to 5 L. Repeat CT scan revealed loculated pleural effusions (Figure 3). Thoracentesis was attempted but only 40 ml bloody fluid was drained.

Thoracoscopy revealed multiloculated pleural effusions with significant visceral pleural thickening and the patient underwent partial decortication. Pathology report revealed pleural thickening and fibrosis with surrounding pulmonary parenchyma revealing diffuse alveolar damage, lymphoplasmacytic infiltrates, and increased IgG4-positive plasma cells with fibrinous adhesions. At this time, blood IgG4 level was 268 mg/dl. Autoimmune, malignant and genetic conditions with similar presentation were excluded. The patient was diagnosed with IgG4-RD affecting the lungs and pleura, non-pulmonary involvement was not found. He was referred to the pulmonology clinic for further management but he was lost to follow-up.

**DISCUSSION**

Pfizer-BioNTech COVID-19 vaccine is given intramuscularly to individuals aged 5 years or older in two doses 3 weeks apart. Local and systemic adverse effects are usually mild. There was only one case report of recurrence of IgG4-related nephritis following second dose of Pfizer COVID-19 vaccine. This is the first reported case of IgG4-related pulmonary and pleural disease after Pfizer COVID-19 vaccine.

The pathogenesis of IgG4-RLD remains unclear. Autoimmunity is a trigger with a key role of T helper-2 cell. The vaccine promotes potent immune response by stimulating robust antigen-specific T-cell responses including T follicular helper cells, and potent germinal centre B-cell responses leading to neutralizing antibody production. The antibodies trigger autoimmune reaction secondary to molecular mimicry. The SARS-CoV-2 spike protein shares homology with several human proteins including human alveolar surfactant-related proteins, which may be subject to off-target immune attack after vaccination and subsequent pulmonary pathology.

Four patterns are observed in IgG4-RLD, which include mediastinal, parenchymal, pleural, and airway involvement. Mediastinal and hilar lymphadenopathy are the commonest patterns. Parenchymal involvement was further sub-categorized...
| TABLE 1 | Summary of the laboratory, pulmonary function test and pleural fluid analysis of our case |
|---------|--------------------------------------------------------------------------------------|

### Serum

|                      | Albumin, g/dl | Lactate dehydrogenase (LDH), U/L | Creatinine, mg/dl | Glucose, mg/dl | Total bilirubin, mg/dl | Aspartate amino-transferase (AST), U/L | Alanine amino-transferase (ALT), U/L | IgG4, mg/dl |
|----------------------|---------------|---------------------------------|-------------------|----------------|-----------------------|----------------------------------------|-------------------------------------|-------------|
| Total protein, g/dl  | 7.1           | 2.3                             | 190               | 0.9            | 83                    | 0.5                                    | 31                                   | 12          |
|                     |               |                                 |                   |                |                       |                                        |                                      | 268         |

### Pleural fluid

| Colour and appearance | White blood cell (WBC)/ml | Segmented cell | Lymphocyte | Monocyte/macrophage | Eosinophil | Lactate dehydrogenase (LDH), U/L | Triglyceride, mmol/L | Albumin, g/dl | Total protein, g/dl | Cholesterol, mg/dl |
|-----------------------|---------------------------|----------------|------------|--------------------|------------|---------------------------------|---------------------|---------------|---------------------|--------------------|
| Yellow and Hazy       | 3507                      | 4%             | 90%        | 5%                 | 1%         | 168                             | 16                  | 1.7           | 5.8                 | 37                 |

### Pulmonary function test

| Forced vital capacity (FVC) | Forc e expired volume in 1 s (FEV1) | FEF (%) | Peak expiratory flow (PEF) (%) | FEV1/FVC | Total lung capacity (TLC) | Residual volume (RV) | RV/TLC | Diffusion capacity of the lungs for carbon monoxide (DLCO) | DLCO/Alveolar volume (DL/VA) |
|-----------------------------|-----------------------------------|---------|--------------------------------|----------|------------------------|----------------------|--------|-------------------------------------------------------------|--------------------------------|
| 80.9%                       | 68.9%                             | 47.4%   | 64.7%                         | 65        | 77.7                   | 74.1                  | 36.45  | 40.4%                                                        | 50.4%                           |
into: (I) solid nodular type; (II) round ground-glass opacity type; (III) alveolar interstitial type; and (IV) bronchovascular type. Pleural effusion or nodules is uncommon. Airway involvement is rare, including tracheobronchial stenosis and traction bronchiectasis. In our patient, there was pleural effusion with atelectasis.

The definite diagnosis of IgG4-RLD relies on histopathological analysis. The key morphological features are dense lymphoplasmacytic infiltrates with collagenised fibrosis and active fibroblastic proliferation. Patients who fulfill the following three criteria are diagnosed as having IgG4-RD: consistent organ involvement or damage; serum IgG4 level of >135 mg/dl; and histopathology showing marked lymphoplasmacytic infiltration, fibrosis. Our case fulfilled all three comprehensive diagnostic criteria and involved lung; therefore, the diagnosis of IgG4-RLD was made.

The mainstay treatment for IgG4-RLD is corticosteroid therapy, and most patients have favourable response in 2 weeks. The usual dose for oral prednisone is between 0.6 and 1 mg/kg/day, and then gradually tapered every 2–4 weeks to maintain a dose of 2.5–5 mg/day and then discontinued within 3 years. For steroid-refractory patients, immunosuppressants or anti CD20 antibody can be considered.

As the worldwide COVID-19 vaccination continues to accelerate, it is probable to see more autoimmune events. However, due to reporting bias and pre-existing undiagnosed autoimmune lung disease, true incidence of IgG4-RLD will be difficult to determine. As multiple doses of vaccines are now being offered, close observation will be needed. Anyone with rapidly progressive lung or pleural disease after COVID 19 vaccine, more aggressive approach for diagnosis is recommended so diseases such as IgG4-RLD cannot be missed and prompt treatment can be started to mitigate this disease.

**CONFLICT OF INTEREST**
None declared.

**DATA AVAILABILITY STATEMENT**
The data that support the findings of this study are available from the corresponding author upon reasonable request.

**ETHICS STATEMENT**
The authors declare that appropriate written informed consent was obtained for the publication of this manuscript and accompanying images.

**ORCID**
Saria Tasnim https://orcid.org/0000-0003-0334-4776

**REFERENCES**
1. Maria TM, Federica DT, Massimiliano DA, Alessandra O. Overview of the main anti-SARS-CoV-2 vaccines: mechanism of action, efficacy and safety. Infect Drug Resist. 2021;14:3459–76. https://doi.org/10.2147/IDR.S315727
2. Christophe M, Delphine K, Christine KA, Aurélie F, Gilles B, Mohamed H. Relapse of IgG4-related nephritis following mRNA COVID-19 vaccine. Kidney Int. 2021;100(2):P465–6. https://doi.org/10.1016/j.kint.2021.06.002
3. Vojdani A, Vojdani E, Kharrazian D. Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: implications for autoimmune diseases. Front Immunol. 2020;11:617089.
4. Ryu JH, Sekiguchi H, Yi ES. Pulmonary manifestations of immunoglobulin G4-related sclerosing disease. Eur Respir J. 2012;39:180–6.
5. Campbell SN, Rubio E, Loschner AL. Clinical review of pulmonary manifestations of IgG4-related disease. Ann Am Thorac Soc. 2014;11:1466–75.

**How to cite this article:** Tasnim S, Al-Jobory O, Hallak A, Bharadwaj T, Patel M. IgG4 related pleural disease: Recurrent pleural effusion after COVID-19 vaccination. Respirology Case Reports. 2022;10: e01026. https://doi.org/10.1002/rcr2.1026